Banca de DEFESA: VICTORIA LOUISE PINTO FREIRE
Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : VICTORIA LOUISE PINTO FREIRE
DATE: 12/12/2022
TIME: 09:00
LOCAL: Link de acesso para videoconferência: meet.google.com/kbg-ykuf-zam
TITLE:
NANOEMULSIONS CONTAINING PHYTOL AS PHARMACOLOGICAL ALTERNATIVE FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS
KEY WORDS:
Nanoemulsion; Leishmaniasis; Phytol.
PAGES: 85
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:
Leishmaniasis is considered one of the main neglected diseases in the world, with large numbers
of cases annually, it is caused by protozoa of the genus Leishmania spp. and affects mainly
populations in poorer countries. The treatment of the disease is very limited, toxic to the patient,
high cost and the parasite is resistant to chemotherapy. In this way, trying to solve problems
such as the side effects of drugs already in use, reducing drug resistance and improving existing
treatments, pharmaceutical nanotechnology appears with drug delivery systems on a
nanometric scale, as is the case of nanoemulsions (NE). At the same time, alternative
leishmanicidal active principles have been sought to treat the disease, such as phytol, which is
a component of chlorophyll from the diterpene class, which is found abundantly in nature and
has a wide range of proven biological activities. Thus, the present study aims to develop NE
containing biocompatible phytol by the phase inversion emulsification technique, to evaluate
the effect of the composition on the physical-chemical parameters of the nanoemulsions, to
observe the long-term and accelerated stability of the systems obtained with and without the
active, also observe the cytocompatible profile in cells and hemolytic and the in vitro capacity
of these antileishmanial systems. Thus, it was observed that the EN developed were stable over
the long term and under accelerated conditions, with adequate macroscopic and
physicochemical parameters, also presenting a cytocompatible profile with the cell line tested
and in the hemolysis test, suggesting safety for system administration in in vivo study. It was
also observed that the developed NE had a good antiparasitic activity and superior to the free
drug. Therefore, the NE produced proved to be a promising drug for the treatment of cutaneous
leishmaniasis, proving to be safe and effective.
COMMITTEE MEMBERS:
Presidente - 1639820 - ARNOBIO ANTONIO DA SILVA JUNIOR
Externo ao Programa - 2213126 - VALTER FERREIRA DE ANDRADE NETO - UFRNExterno à Instituição - DOUGLAS DOURADO OLIVEIRA - Fiocruz - PE